IBDEI2G2 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41456,1,4,0)
 ;;=4^Z80.3
 ;;^UTILITY(U,$J,358.3,41456,2)
 ;;=^5063347
 ;;^UTILITY(U,$J,358.3,41457,0)
 ;;=Z80.41^^159^2005^38
 ;;^UTILITY(U,$J,358.3,41457,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41457,1,3,0)
 ;;=3^Family Hx of Malig Neop of Ovary
 ;;^UTILITY(U,$J,358.3,41457,1,4,0)
 ;;=4^Z80.41
 ;;^UTILITY(U,$J,358.3,41457,2)
 ;;=^5063348
 ;;^UTILITY(U,$J,358.3,41458,0)
 ;;=Z80.42^^159^2005^39
 ;;^UTILITY(U,$J,358.3,41458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41458,1,3,0)
 ;;=3^Family Hx of Malig Neop of Prostate
 ;;^UTILITY(U,$J,358.3,41458,1,4,0)
 ;;=4^Z80.42
 ;;^UTILITY(U,$J,358.3,41458,2)
 ;;=^5063349
 ;;^UTILITY(U,$J,358.3,41459,0)
 ;;=Z80.43^^159^2005^40
 ;;^UTILITY(U,$J,358.3,41459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41459,1,3,0)
 ;;=3^Family Hx of Malig Neop of Testis
 ;;^UTILITY(U,$J,358.3,41459,1,4,0)
 ;;=4^Z80.43
 ;;^UTILITY(U,$J,358.3,41459,2)
 ;;=^5063350
 ;;^UTILITY(U,$J,358.3,41460,0)
 ;;=Z80.6^^159^2005^32
 ;;^UTILITY(U,$J,358.3,41460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41460,1,3,0)
 ;;=3^Family Hx of Leukemia
 ;;^UTILITY(U,$J,358.3,41460,1,4,0)
 ;;=4^Z80.6
 ;;^UTILITY(U,$J,358.3,41460,2)
 ;;=^5063354
 ;;^UTILITY(U,$J,358.3,41461,0)
 ;;=Z80.8^^159^2005^37
 ;;^UTILITY(U,$J,358.3,41461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41461,1,3,0)
 ;;=3^Family Hx of Malig Neop of Organs/Systems
 ;;^UTILITY(U,$J,358.3,41461,1,4,0)
 ;;=4^Z80.8
 ;;^UTILITY(U,$J,358.3,41461,2)
 ;;=^5063356
 ;;^UTILITY(U,$J,358.3,41462,0)
 ;;=Z81.8^^159^2005^42
 ;;^UTILITY(U,$J,358.3,41462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41462,1,3,0)
 ;;=3^Family Hx of Mental/Behavioral Disorders
 ;;^UTILITY(U,$J,358.3,41462,1,4,0)
 ;;=4^Z81.8
 ;;^UTILITY(U,$J,358.3,41462,2)
 ;;=^5063363
 ;;^UTILITY(U,$J,358.3,41463,0)
 ;;=Z82.3^^159^2005^49
 ;;^UTILITY(U,$J,358.3,41463,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41463,1,3,0)
 ;;=3^Family Hx of Stroke
 ;;^UTILITY(U,$J,358.3,41463,1,4,0)
 ;;=4^Z82.3
 ;;^UTILITY(U,$J,358.3,41463,2)
 ;;=^5063367
 ;;^UTILITY(U,$J,358.3,41464,0)
 ;;=Z82.49^^159^2005^31
 ;;^UTILITY(U,$J,358.3,41464,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41464,1,3,0)
 ;;=3^Family Hx of Ischemic Heart Disease/Circulatory System
 ;;^UTILITY(U,$J,358.3,41464,1,4,0)
 ;;=4^Z82.49
 ;;^UTILITY(U,$J,358.3,41464,2)
 ;;=^5063369
 ;;^UTILITY(U,$J,358.3,41465,0)
 ;;=Z82.5^^159^2005^22
 ;;^UTILITY(U,$J,358.3,41465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41465,1,3,0)
 ;;=3^Family Hx of Asthma/Chronic Lower Respiratory Diseases
 ;;^UTILITY(U,$J,358.3,41465,1,4,0)
 ;;=4^Z82.5
 ;;^UTILITY(U,$J,358.3,41465,2)
 ;;=^5063370
 ;;^UTILITY(U,$J,358.3,41466,0)
 ;;=Z82.61^^159^2005^21
 ;;^UTILITY(U,$J,358.3,41466,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41466,1,3,0)
 ;;=3^Family Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,41466,1,4,0)
 ;;=4^Z82.61
 ;;^UTILITY(U,$J,358.3,41466,2)
 ;;=^5063371
 ;;^UTILITY(U,$J,358.3,41467,0)
 ;;=Z82.69^^159^2005^44
 ;;^UTILITY(U,$J,358.3,41467,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41467,1,3,0)
 ;;=3^Family Hx of Musculoskeletal System/Connective Tissue
 ;;^UTILITY(U,$J,358.3,41467,1,4,0)
 ;;=4^Z82.69
 ;;^UTILITY(U,$J,358.3,41467,2)
 ;;=^5063373
 ;;^UTILITY(U,$J,358.3,41468,0)
 ;;=Z83.3^^159^2005^28
 ;;^UTILITY(U,$J,358.3,41468,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41468,1,3,0)
 ;;=3^Family Hx of Diabetes Mellitus
 ;;^UTILITY(U,$J,358.3,41468,1,4,0)
 ;;=4^Z83.3
 ;;^UTILITY(U,$J,358.3,41468,2)
 ;;=^5063379
 ;;^UTILITY(U,$J,358.3,41469,0)
 ;;=Z83.2^^159^2005^24
 ;;^UTILITY(U,$J,358.3,41469,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41469,1,3,0)
 ;;=3^Family Hx of Blood/Immune Mechanism Diseases
